Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Results
Compare outcome data across trials and publications.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Road to Access
Science, regulation, and economics on the path to patient access.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
This re-analysis of a Phase I randomised controlled trial (n=89) investigated predictors of mystical and challenging experiences in healthy volunteers receiving psilocybin. It finds that dosage was the strongest predictor of intensity for both experience types, while older age was associated with fewer challenging experiences and neuroticism correlated with challenging experiences only at the higher dose.
This review (2020) investigates the potential of ketamine for the treatment of bipolar disorder (BD). Although studies with BD and ketamine are limited, studies on (unipolar) depression and neurological effects of ketamine (e.g. BDNF levels) show positive signals.
This review (2020) details the background and therapeutic challenges associated with treatment-resistant depression. A wide range of treatments are evaluated, including novel therapeutics such as ketamine and psilocybin.
This retrospective chart review (n=27) investigates the efficacy and safety of rapid infusion of esketamine in patients with treatment-resistant depression (TRD) and bipolar depression (BD). The study found that rapid infusion of esketamine is not the best choice for treatment-resistant depression due to tolerability issues. Additionally, patients reported dissociative symptoms ranging from mild to severe and found them to be disturbing.
This meta-analysis (2016, 9 RCT studies, n=368) suggests ketamine is an effective short-term treatment for major depressive disorder (MDD).
This double-blind, cross-over, placebo-controlled study (n=27) investigated the antidepressant and psychotomimetic effects of a single ketamine infusion (38mg/70kg) in patients diagnosed with major depressive disorder (MDD). Ketamine infusion induced acute psychotomimetic symptoms, which correlated with alleviating negative mood ratings and improving depression symptoms in the days after.